Pollock, Carol;
Carrero, Juan-Jesus;
Kanda, Eiichiro;
Ofori-Asenso, Richard;
Chen, Hungta;
Garcia Sanchez, Juan Jose;
Pentakota, Surendra;
... Wheeler, David C; + view all
(2024)
Baseline Characteristics of the DISCOVER CKD Prospective Cohort.
Advances in Therapy
10.1007/s12325-024-03028-z.
(In press).
Preview |
Text
Wheeler_s12325-024-03028-z.pdf Download (2MB) | Preview |
Abstract
INTRODUCTION: Real-world data from patients with chronic kidney disease (CKD) are limited, particularly regarding clinical management, treatment patterns and health-related quality of life (HRQoL) in the context of new therapies and updated standard of care guidelines. METHODS: DISCOVER CKD is an observational cohort study enrolling adult patients with CKD, defined by an International Classification of Diseases, 10th Revision code, or with two estimated glomerular filtration rate measures < 75 ml/min/1.73 m2 recorded 91-730 days apart. We describe the demographics, baseline characteristics and patient-reported outcomes of patients enrolled in the prospective phase. RESULTS: Of 1052 patients (mean age 62.5 years; 36.9% female) enrolled from the USA, UK, Spain, Italy, Sweden and Japan, 727 (69.1%) had stage 2-3b CKD and 325 (30.9%) had stage 4-5 CKD. Overall, 72.4%, 43.0% and 37.5% of patients had histories of hypertension, diabetes and hyperlipidaemia, respectively. In total, 58.7% and 14.0% were receiving renin-angiotensin-aldosterone system inhibitors (RAASi) and sodium-glucose co-transporter 2 inhibitors (SGLT2i), respectively. Compared with patients with stage 2-3b CKD, patients with stage 4-5 CKD reported numerically greater symptom burden across all 11 symptoms measured, numerically worse HRQoL across all eight categories measured using the 36-item Short Form (SF-36) questionnaire, and numerically greater impairment at work across all four categories measured using the Work Productivity and Activity Impairment chronic kidney disease (WPAI-CKD) questionnaire. Compared with patients with stage 2-3b CKD, a higher proportion of patients with stage 4-5 CKD had anaemia, hyperkalaemia and oedema (49.8% vs. 16.9%, 21.8% vs. 8.4% and 17.5% vs. 9.5%, respectively). CONCLUSIONS: These contemporary real-world data from six countries highlight the substantial symptom, medication and psychosocial burden associated with CKD, and continued gaps in treatment. Graphical abstract available for this article. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT04034992.
| Type: | Article |
|---|---|
| Title: | Baseline Characteristics of the DISCOVER CKD Prospective Cohort |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s12325-024-03028-z |
| Publisher version: | https://doi.org/10.1007/s12325-024-03028-z |
| Language: | English |
| Additional information: | Open Access: This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. - PLEASE NOTE: This article was originally published electronically on the publisher’s internet portal (currently SpringerLink) on November 29, 2024 without open access. After publication, the licence status was changed to a Creative Commons Attribution-NonCommercial 4.0 International License (see the correction at https://doi.org/10.1007/s12325-025-03107-9 published on 03 February 2025) |
| Keywords: | Baseline characteristics, Chronic kidney disease, DISCOVER CKD, Epidemiology, Patient-reported outcomes |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10204684 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
